Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.120
-0.010 (-0.88%)
At close: Dec 5, 2025, 4:00 PM EST
1.090
-0.030 (-2.68%)
After-hours: Dec 5, 2025, 7:48 PM EST
Galmed Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Galmed Pharmaceuticals.
Price Target: $0.00 (0.00%)
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Galmed Pharmaceuticals is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 4, 2025 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $48 | Hold → Strong Buy | Upgrades | $48 | +4,185.71% | Jul 24, 2023 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 8, 2022 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $900 → $180 | Strong Buy → Hold | Downgrades | $900 → $180 | +15,971.43% | Aug 8, 2022 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 18, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.36
from -8.08
EPS Next Year
-0.87
from -2.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.43 | -0.89 | |
| Avg | -2.36 | -0.87 | |
| Low | -2.26 | -0.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.